Strides Pharma Q4 Results: Co still in the red, but loss narrows to Rs 14 crore
The US business reported a third consecutive quarter of over $60 million in revenues in Q4FY23, while other regulated markets recorded the highest quarterly sales of $48 million. The company attributed the US sales to new product introductions and solid base performance,
